Associations between national development indicators and the age profile of people who inject drugs: results from a global systematic review and meta-analysis

Lindsey A Hines, Adam Trickey, Janni Leung, Sarah Larney, Amy Peacock, Louisa Degenhardt, Samantha Colledge, Matthew Hickman, Jason Grebely, Evan B Cunningham, Jack Stone, Kostyantyn Dumchev, Paul Griffiths, Peter Vickerman, Richard P Mattick, Michael Lynskey

Research output: Contribution to journalArticlepeer-review

19 Citations (SciVal)

Abstract

BACKGROUND: Globally, an estimated 15·6 million people inject drugs. We aimed to investigate global variation in the age profile of people who inject drugs (PWID), identify country-level factors associated with age of PWID, and assess the association between injecting drug use (IDU) in young people and rates of injecting and sexual risk behaviours at the country level.

METHODS: We derived data from a previously published global systematic review done in April, 2016 (and updated in June, 2017) on the percentage of young PWID, duration of IDU, average age of PWID, average age at IDU initiation, and the percentage of PWID reporting sexual and injecting risk behaviours. We also derived national development indicators from World Bank data. We estimated the percentage of young PWID for each country, using a random-effects meta-analysis (DerSimonian-Laird methodology) and generated pooled regional and global estimates for all indicators of IDU in young people. We used univariable and multivariable generalised linear models to test for associations between the age indicators and country urban population growth, youth unemployment percentage, the percentage of PWID who are female, the percentage of the general population aged 15-24 years, Gini coefficient, opioid substitution therapy coverage (per PWID per year), gross domestic product (GDP) per capita (US$1000), and sexual and injecting risk behaviours.

FINDINGS: In the original systematic review, data on age of PWID was reported in 741 studies across 93 countries. Globally, 25·3% (95% uncertainty interval [UI] 19·6-31·8) of PWID were aged 25 years or younger. The highest percentage of young PWID resided in eastern Europe (43·4%, 95% UI 39·4-47·4), and the lowest percentage resided in the Middle East and north Africa (6·9%, 5·1-8·8). At the country level, in multivariable analysis higher GDP was associated with longer median injecting duration (0·11 years per $1000 GDP increase, 95% CI 0·04-0·18; p=0·002), and older median age of PWID (0·13 years per $1000 increase, 0·06-0·20; p<0·0001). Urban population growth was associated with higher age at IDU initiation (1·40 years per annual percentage change, 0·41-2·40). No associations were identified between indicators of IDU in young people and youth unemployment, Gini coefficient, or opioid substitution therapy coverage provision at the country level. No associations were identified between injecting and sexual risk behaviours and age of PWID.

INTERPRETATION: Variation in the age profile of PWID was associated with GDP and urbanisation. Regions with the highest prevalence of young PWID (aged ≤25 years) had low coverage of interventions to prevent the spread of blood-borne viruses. Data quality highlights the need for improvements in monitoring of PWID populations.

FUNDING: Australian National Drug and Alcohol Research Centre, Australian National Health and Medical Research Council, Open Society Foundation, WHO, the Global Fund, UNAIDS, National Institute for Health Research Health Protection Research Unit for Evaluation of Interventions, Wellcome Trust.

Original languageEnglish
Pages (from-to)e76-e91
Number of pages16
JournalThe Lancet. Global Health
Volume8
Issue number1
DOIs
Publication statusPublished - 31 Jan 2020
Externally publishedYes

Bibliographical note

LAH reports grants from the Australian Government and Wellcome Trust during the conduct of the study. SL has received investigator-initiated untied educational grants from Indivior. AP reports grants from the WHO, Global Fund, UNAIDS, and the Australian Government Department of Health during the conduct of the study, and has received investigator-initiated untied educational grants from Mundipharma and Seqirus. LD reports investigator-initiated untied educational grants for studies of opioid medications in Australia from Indivior, Mundipharma, and Seqirus. MH reports personal fees from MSD and Gilead Sciences, outside the submitted work. JG is a consultant and advisor for and has received research grants from AbbVie, Cepheid, Gilead Sciences, and MSD. All other authors declare no competing interests.

Keywords

  • Adolescent
  • Adult
  • Age Factors
  • Aged
  • Aged, 80 and over
  • Female
  • Global Health/statistics & numerical data
  • Humans
  • Male
  • Middle Aged
  • Prevalence
  • Risk-Taking
  • Substance Abuse, Intravenous/epidemiology
  • Young Adult

Fingerprint

Dive into the research topics of 'Associations between national development indicators and the age profile of people who inject drugs: results from a global systematic review and meta-analysis'. Together they form a unique fingerprint.

Cite this